Drug
Pazopanib clinical trials
Also written Votrient, GW786034B and GW786034.
- studies test it
- 220
- open now
- 10
- in phase 3
- 13
- first study started
- 2002
Keep track of what changes. Save the pazopanib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Votrient
- 86
Combined with it in one product
Studies by the year they started
219 studies that test it; most in 2010 (35)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2004 | 1 |
| 2005 | 4 |
| 2006 | 12 |
| 2007 | 11 |
| 2008 | 14 |
| 2009 | 12 |
| 2010 | 35 |
| 2011 | 34 |
| 2012 | 29 |
| 2013 | 14 |
| 2014 | 8 |
| 2015 | 18 |
| 2016 | 6 |
| 2017 | 5 |
| 2018 | 2 |
| 2019 | 3 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 73
- Phase 2
- 144
- Phase 3
- 13
- Phase 4
- 4
- No phase
- 7
What it is tested for
Each study’s main condition, where its own words name it.
- Sarcoma
- 26
Who runs them
Industry 56 · Other 164
GlaxoSmithKline (42) · National Cancer Institute (NCI) (25) · M.D. Anderson Cancer Center (9) · Novartis Pharmaceuticals (9) · Samsung Medical Center (7) · Centre Leon Berard (4) · Washington University School of Medicine (4) · Northwestern University (3)
Often tested with
Tested in the same studies.
Paclitaxel (12) · Everolimus (9) · Sunitinib (9) · Gemcitabine (8) · Lapatinib (8) · Sorafenib (6) · Doxorubicin (5) · Topotecan (5)
Studies
Open first, then newest update. How each study uses pazopanib is read from its arms, and is right about nine times in ten.
Testing it · 220
- Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent SarcomaRecruitingNot applicableM.D. Anderson Cancer CenterNCT04199026Written as Pazopanib
- A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue SarcomasRecruitingPhase 1M.D. Anderson Cancer CenterNCT07444619Written as Pazopanib
- NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)RecruitingPhase 1/2St. Jude Children's Research HospitalNCT06239272Written as Pazopanib
- Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentRecruitingPhase 2Centre Leon BerardNCT02029001Written as Pazopanib (800 mg QD)
- Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue SarcomaRecruitingPhase 2Yonsei UniversityNCT05679921Written as pembrolizumab, pazopanib
- Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)RecruitingPhase 1/2Tianjin Medical University Second HospitalNCT06895733Written as Pazopanib Oral Tablet
- Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or AdolescentsRecruitingPhase 2Shandong Cancer Hospital and InstituteNCT06816771Written as pazopanib
- OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older AdultsNot yet recruitingPhase 4University Medical Center GroningenNCT05949424Written as Pazopanib
- Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic TelangiectasiaNot yet recruitingPhase 1/2Cure HHTNCT03850730Written as Pazopanib
- Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid TumorsNot yet recruitingPhase 1/2Samsung Medical CenterNCT03628131Written as Pazopanib
- Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After SurgeryActive, not recruitingPhase 3National Cancer Institute (NCI)NCT01575548Written as Pazopanib Hydrochloride
- Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid TumorsActive, not recruitingPhase 2National Cancer Institute (NCI)NCT01841736Written as Pazopanib Hydrochloride
- Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid TumorsActive, not recruitingPhase 1National Cancer Institute (NCI)NCT01552356Written as Pazopanib Hydrochloride
- Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START TrialActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT01217931Written as Pazopanib
- Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid CarcinomaCompletedPhase 2Centre Leon BerardNCT01813136Written as Continuous pazopanib (Arm A)
- HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue SarcomasActive, not recruitingPhase 1/2Centre Leon BerardNCT05180695Written as Pazopanib
- Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by SurgeryCompletedPhase 2/3National Cancer Institute (NCI)NCT02180867Written as Pazopanib
- Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma MultiformeActive, not recruitingPhase 1/2Centre Antoine LacassagneNCT02331498Written as Pazopanib
- Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG CriteriaTerminatedPhase 1Institut Claudius RegaudNCT01642017Written as Pazopanib
- Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell CarcinomaCompletedPhase 4Institut Claudius RegaudNCT02555748Written as Pazopanib
See all 220 studies that test pazopanib →
Given in every arm · 14 — pazopanib is usual care beside what is tested
- A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell CarcinomaRecruitingPhase 2Imbioray (Hangzhou) Biomedicine Co., Ltd.NCT07087158Written as Pazopanib
- A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)RecruitingPhase 3Xynomic Pharmaceuticals, Inc.NCT03592472Written as Pazopanib
- A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsCompletedPhase 1Eli Lilly and CompanyNCT02009449Written as Pazopanib
- Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal CancerCompletedPhase 1/2European Organisation for Research and Treatment of Cancer - EORTCNCT01402271Written as pazopanib hydrochloride
- Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by SurgeryTerminatedPhase 2Academic and Community Cancer Research UnitedNCT03334409Written as Pazopanib Hydrochloride
- PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian CancerTerminatedPhase 1/2The Christie NHS Foundation TrustNCT02055690Written as Pazopanib
- Pazopanib Tolerability When Given With FoodCompletedPhase 1Radboud University Medical CenterNCT02138526Written as pazopanib
- Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced AngiosarcomaCompletedPhase 3Tracon Pharmaceuticals Inc.NCT02979899Written as Votrient
- Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone MetsCompletedPhase 1Dana-Farber Cancer InstituteNCT02406521Written as Pazopanib
- A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid TumorsCompletedPhase 1GlaxoSmithKlineNCT00619424Written as pazopanib
- Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)CompletedPhase 1GlaxoSmithKlineNCT00387387Written as Pazopanib
- Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single Dose Of Pazopanib (GW786034) Eye DropsCompletedPhase 1GlaxoSmithKlineNCT00659555Written as pazopanib eye drops
- Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone TherapyCompletedPhase 2National Cancer Institute (NCI)NCT00486642Written as Pazopanib Hydrochloride
- Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid TumorsCompletedPhase 1M.D. Anderson Cancer CenterNCT01454804Written as Pazopanib
As the comparator · 8 — what is tested is compared with pazopanib
- A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)RecruitingPhase 3Intensity Therapeutics, Inc.NCT06263231Written as Pazopanib
- Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare SubtypeRecruitingPhase 3Centre Leon BerardNCT04741438Written as Pazopanib Oral Tablet [Votrient]
- Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped WorkingActive, not recruitingPhase 2/3National Cancer Institute (NCI)NCT05432791Written as Pazopanib
- Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)CompletedPhase 3Incyte CorporationNCT03260894Written as Pazopanib
- Phase 3 Study to Treat Patients With Soft Tissue SarcomasCompletedPhase 3ImmunityBio, Inc.NCT02049905Written as Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
- Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease ControlTerminatedPhase 2AIO-Studien-gGmbHNCT02959554Written as Pazopanib
- Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal TumorsStatus unknownNot applicableUniversity Hospital, GrenobleNCT03571438Written as Pazopanib
- Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical CancerCompletedPhase 2GlaxoSmithKlineNCT00430781Written as pazopanib (GW786034)
Codes
What other systems call pazopanib · ClinicalTrials.gg INT005030
- MeSH (NLM) C516667pazopanibConfirmed NLM, Wikidata
- UNII (FDA) 7RN5DR86CKPAZOPANIBConfirmed FDA, NLM, Wikidata
- RxNorm 714438Confirmed FDA, Wikidata
- Wikidata Q7157043pazopanibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C74547PazopanibOne source FDA
- DrugBank DB06589One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C516667 | pazopanib | Confirmed NLM, Wikidata |
| UNII (FDA) | 7RN5DR86CK | PAZOPANIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 714438 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7157043 | pazopanib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C74547 | Pazopanib | One source FDA |
| DrugBank | DB06589 | — | One source Wikidata |
Also registered as pazopanib hydrochloride (UNII 33Y9ANM545 · RxNorm 732187).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.